Intramedullary spinal cord implantation of human CD34+ umbilical cord-derived cells in ALS.

Departments of Neurology , Hannover , Germany.
Amyotrophic Lateral Sclerosis (Impact Factor: 2.37). 08/2011; 12(5):325-30. DOI: 10.3109/17482968.2011.580850
Source: PubMed

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with marginal therapeutic options. Degeneration of motor neurons in the primary motor cortex, brainstem and spinal cord lead to rapidly progressive paralysis and finally to death due to respiratory failure. As pharmacological therapies have failed to provide sufficient neuroprotective effects in ALS, transplantation of stem or progenitor cells is considered a promising treatment strategy. Cell transplantation approaches in ALS mainly aim to generate a neuroprotective environment for degenerating motor neurons by transplantation of non-neuronal cells, rather than to replace lost motor neurons. We present a 63-year-old male patient suffering from ALS who underwent intramedullary thoracic spinal cord implantation of human CD34(+) umbilical cord-derived haematopoietic progenitor cells with a three-year follow up after transplantation.


Available from: Eva M Weissinger, Feb 09, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) and other cellular therapies are a promising alternative in the treatment of neurodegenerative diseases. Preclinical data suggests that MSCs may have therapeutic potential for ALS, a lethal neurodegenerative disease involving a rapidly progressive death of motor neurons. However, the positive results of cell therapy in animal models have not been con fi rmed by the phase I/II clinical trials performed to date. The results from patients’ off-label cell treatments in clinics worldwide, which are the majority of cases, have also failed to provide grounds for optimism. We reviewed the clinical trials published to date, and social networking tools giving details of ALS patients’ experiences with off-label cell treatments. There is no objective evidence that MSC therapy can halt or slow down the course of the disease. This conclusion is supported by a recent metaanalysis of a larger series with intraspinal administration, with a 9-year follow-up, which detected no clear clinical bene fi ts. Future trials should be regulated by an international consortium of stem cell networks to ensure regulatory oversight of these modern therapies.
    2ond Edition edited by Lucas G. Chase & Mohan C. Vemuri, 12/2012; Springer New York Heidelberg Dordrecht London., ISBN: ISBN 978-1-62703-199-8 ISBN 978-1-62703-200-1 (eBook
  • [Show abstract] [Hide abstract]
    ABSTRACT: Administration of stem cells is a promising novel approach for treatment of neurodegenerative diseases. For in vivo monitoring of transplanted cells, non-invasive imaging modalities are needed. In this study we determined the tracking efficiency of a superparamagnetic iron oxide (SPIO)-labelled canine cell line (MTH53A) in vitro as well as the human CD34(+) umbilical cord blood stem cells (hUCBCs) in vitro and in vivo efficiency by magnetic resonance imaging (MRI). SPIO-labelled MTH53A cells and hUCBCs were scanned in agar gel phantoms at 1.0 T or 7.0 T. For in vivo detection, 100,000 labelled hUCBCs were injected into the spinal cord of a transgenic amyotrophic lateral sclerosis (ALS) mouse and scanned at 7.0 T. In vitro, 100,000 MTH53A cells and 250,000 hUCBCs were visible at 1.0 T. Scanning with 7.0 T revealed 25,000 detectable MTH53A cells. In vivo, 7.0 T MRI showed clear signals of 100,000 implanted cells. MRI combined with SPIO nanoparticles provides valuable potential for non-invasive, non-toxic in vivo tracking of cells implanted into the spinal cord.
    In vivo (Athens, Greece) 01/2012; 26(1):31-8. · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although used mainly for transplantation of hematopoietic stem cells in the treatment of blood disorders, UCB-based therapies are now being used increasingly for novel applications in non-hematopoietic diseases and as a form of cellular regenerative therapy or immune modulation. We performed a systematic scoping review by searching Medline, EMBASE and the Cochrane Library for published articles and we searched and the World Health Organization International Clinical Trials Registry Platform to describe the breadth of published studies and ongoing clinical activity in umbilical cord-based cellular therapy for regenerative therapy and immune modulation. The most commonly published area of expertise in the use of UCB-derived cellular transplantation for novel indications is for neurological disorders and this remains the most active area of study in ongoing registered trials. An increasingly broad range of disorders, however, is reflected in ongoing registered trials which suggests greater activity, interest and investment in UCB-derived cellular therapy. Interestingly, adult patients comprise the majority of patients reported in published reports and registered ongoing clinical studies continue to enroll predominantly adult subjects. Geographically, Asian countries appear most active in UCB-derived cellular therapy and our analysis of ongoing studies suggests this trend will likely continue. Regular assessment of published and ongoing activity in UCB transplantation for emerging novel indications will be critical for informing UCB banking establishments and funding agencies to guide changes in banking practices related to emerging trends in cell therapy.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 09/2013; 20(1). DOI:10.1016/j.bbmt.2013.09.010 · 3.35 Impact Factor